

MARKET REPORT



PARP Inhibitors in Oncology

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



PARP Inhibitors in Oncology

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)1300 321501 or **Email:** reportstore@bioportfolio.com

PARP Inhibitors in Oncology

PARP Inhibitors in Oncology

Summary

Since hitting the market in 2015, drugs that target poly (ADP-ribose) polymerase (PARP) have transformed the clinical management of cancers harboring BRCA-mutations. As more PARP inhibitors have been commercialized, drug developers are turning their attention towards broadening drug labels and exploring combination strategies. This report covers the management of PARP inhibitors in the US, Europe, and Asia, focusing on efficacy and safety comparisons for approved products, current and future indications, and research and development strategies.

Scope

This report combines key opinion leader insight with in-house analyst expertise and research to provide an insight-rich look at PARP inhibitors in the US, Europe, and Asia. Components of the report include -

- Overview of PARP Inhibitors in Oncology: Background, mechanism of action, and clinical development of PARP inhibitors.
- Epidemiology Analysis: Which current and future disease spaces are relevant to PARP inhibitors.
- Marketed PARP Inhibitors: How the currently approved PARP inhibitors compare.
- Pipeline Assessment in the 8MM: What are the pipeline PARP inhibitor products in development in oncology.
- Key Players: What companies are developing PARP inhibitors in oncology.
- Research and Development Strategies: How are PARP inhibitor clinical trials being designed, and what combination strategies are being explored in the US, Europe, and Asia.
- Pricing, Reimbursement, and Regulatory Strategies: What current and future challenges face PARP inhibitors from a payer's perspective.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the PARP inhibitor market in the US, Europe, and Asia.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the portfolios of various competitors.
- Identify areas of unmet need within the PARP inhibitor market to help drive research and development towards future market opportunities.
- Gain insights to help plan and design your clinical trials.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
- Identify key pricing and reimbursement strategies.

Additional Details

Publisher : Global Data

Reference : GDHCHT013

Number of Pages : 116

Report Format : PDF

Publisher Information :



GlobalData »

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for PARP Inhibitors in Oncology

[Report Updated: 18-09-2018]

- Table of Contents1. Preface1.1 Table of Contents 21.2 Abbreviations 41.3 Related Reports 61.4 Upcoming Related Reports 72. Executive Summary 82.1 Key Findings 92.2 KOL Insight on PARP Inhibitor Competitive Landscape 103. Overview - PARP Inhibitors 113.1 The Role of PARP in DNA Repair 133.2 Mechanism of PARP Inhibitors in Cancer 143.3 History of PARP Inhibitor Clinical Development 153.4 PARP Inhibitors in Ovarian Cancer 173.5 PARP Inhibitors in Breast Cancer 203.6 PARP Inhibitors in Prostate Cancer 223.7 PARP Inhibitors in Pancreatic Cancer 233.8 PARP Inhibitors in Other Cancers 253.9 PARP Inhibitor Resistance and Long-Term Effects 264. Epidemiology Analysis 284.1 Epidemiology Analysis - Ovarian Cancer 304.2 Epidemiology Analysis - Breast Cancer 324.3 Epidemiology Analysis - Prostate Cancer 344.4 Epidemiology Analysis - Pancreatic Cancer 364.5 Epidemiology Analysis - Gastric Cancer 385. Marketed PARP Inhibitors 405.1 Timeline of PARP Inhibitors Clinical Development in the 8MM 425.2 Currently Marketed PARP Inhibitors in Oncology 435.3 KOL Input on Marketed PARP Inhibitors 496. Pipeline Assessment in the 8MM 526.1 Assessment of Ongoing Trials of Marketed PARP Inhibitors 546.2 Talazoparib (Pfizer) 566.3 Veliparib (AbbVie) 576.4 Pamiparib (BeiGene) 586.5 2X-121 (Oncology Venture) 596.6 Fluzoparib (Jiangsu Hengrui Medicine Co.) 606.7 PARP Trapping 626.8 KOL Input on Pipeline PARP Inhibitors 637. Key Players 657.1 Companies Developing PARP Inhibitors in Oncology 667.2 Analysis of the Company Portfolio Gap in PARP Inhibitors 677.3 KOL Input on Key Players 688. Clinical Trials Mapping and Design 698.1 Ongoing Clinical Trials of PARP Inhibitors Pipeline 718.2 KOL Input on Challenges in PARP Inhibitor Clinical Trial Design 809. Combination Strategies with PARP Inhibitors 839.1 Overview of Clinical Trials of PARP Inhibitors as Combination Therapy 859.2 Combination Strategy of PARP Inhibitors with Immunooncology 879.3 Combination Strategy of PARP Inhibitors with Angiogenesis Inhibitors 899.4 Combination Strategy of PARP Inhibitors with Chemotherapy 909.5 Combination Strategy of PARP Inhibitors with Other Drugs 9110. Pricing, Reimbursement, and Regulatory Strategy 9210.1 Current Strategies for Oncology Products 9410.2 Differentiating Between Lynparza, Rubraca, and Zejula 9510.3 Future PARP Inhibitors 9710.4 PARP Inhibitor Challenges from US/UK Payers' Perspective 9811. Market Outlook and Future Use 10011.1 Market Outlook 10211.2 Anticipated Key Events in PARP Inhibitors 10511.3 Future Uses of PARP Inhibitors in Oncology 10612. Appendix 10712.1 Sources 10812.2 Methodology 10912.3 Primary Research 11012.4 About the Authors 11212.5 About GlobalData 114

How to Buy...

PARP Inhibitors in Oncology [Report Updated: 18-09-2018]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/225773>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at reportstore@bioportfolio.com or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$7995** | Single User Price
- \$15990** | Site License Price
- \$23985** | Global License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.